SCHEMBL1033122

SCHEMBL1033122

O=C(O)c1cccc2ccc(-c3ccnc(C(F)F)c3)nc12

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 2/20 0.47
▸ AAK1 Q2M2I8 7/20 0.40
▸ KMO O15229 5/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ ALOX12 P18054 1/20 0.39
▸ CIT O14578 1/20 0.38
▸ GAK O14976 1/20 0.38
▸ SLC6A2 P23975 1/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ MKNK1 Q9BUB5 1/20 0.38
▸ LATS2 Q9NRM7 1/20 0.38
▸ BMP2K Q9NSY1 1/20 0.38
▸ ABCG2 Q9UNQ0 1/20 0.38
▸ AURKA O14965 1/20 0.36
▸ ABL1 P00519 1/20 0.35
▸ BCR P11274 1/20 0.35
▸ SRC P12931 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1032405 0.81 PARP1 (0.53) PARP1KMOALDH1A1LMNAAURKA
SCHEMBL1032582 0.81 PARP1 (0.50) PARP1KMOALDH1A1LMNAALOX12
SCHEMBL1033599 0.81 PARP1 (0.50) PARP1KMOALDH1A1LMNAALOX12
SCHEMBL1031182 0.81 SIRT2 (0.48) ALDH1A1LMNA
SCHEMBL1033101 0.80 EGLN1 (0.50) ALDH1A1ABL1BCRSRC
SCHEMBL1033322 0.80 CHRNB2 (0.47) PARP1AAK1ALDH1A1LMNA
SCHEMBL1034654 0.78 RAB9A (0.44) ALDH1A1LMNA
SCHEMBL3151445 0.77 PARP1 (0.61) PARP1ALDH1A1LMNAALOX12
SCHEMBL1033211 0.75 PARP1 (0.77) PARP1ALDH1A1LMNAALOX12
SCHEMBL27945291 0.74 PARP1 (0.74) PARP1ALDH1A1LMNAALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2273992-B1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-05-25 — — EP disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 — — US disclosed
EP-2273992-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2011-01-19 — — EP disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 PARP1 183/4885AAK1 1288/4885KMO 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback